Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The megameric conjugate with nimesulide was tested in vitro on three human cell lines: squamous cell carcinoma (SCC-15) and glioblastoma (U-118 MG) overexpressing cyclooxygenase-2 (COX-2), and normal skin fibroblasts (BJ).
|
31601050 |
2019 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Conjugates overcome apoptosis resistance and sensitized SCC-15 cells to the apoptotic death independently of COX-2/PGE<sub>2</sub> axis.
|
31480608 |
2019 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Immunohistochemistry for cyclooxygenase-2 was performed on a total of 100 oral squamous cell carcinoma formalin-fixed, paraffin-embedded blocks.
|
30674365 |
2018 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Role of COX-2/PGE2 Mediated Inflammation in Oral Squamous Cell Carcinoma.
|
30248985 |
2018 |
Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
COX-2 was neo-expressed in 86.6% of the cases and expression progressively increased from ePP to ePSCC (P = 0.0003) and from well to poorly differentiated (P = 0.033).
|
30270026 |
2018 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Repression of caspase-3 and RNA-binding protein HuR cleavage by cyclooxygenase-2 promotes drug resistance in oral squamous cell carcinoma.
|
27941877 |
2017 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Studies on the Contribution of Cox-2 Expression in the Progression of Oral Squamous Cell Carcinoma and H-Ras Activation.
|
27628320 |
2017 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Moreover, we found that p62 stabilizes COX-2 protein through the p62 ubiquitin-associated domain and that p62 regulates prostaglandin E<sub>2</sub> production <i>in vitro</i> In a syngeneic squamous cell carcinoma mouse model, p62 knockdown inhibited tumor growth and metastasis.
|
28724634 |
2017 |
Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Combined Analysis of Vascular Endothelial Growth Factor Expression with Cyclooxygenase-2 and Mast Cell Density in Oral Squamous Cell Carcinoma.
|
27577989 |
2017 |
Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The present study was undertaken to evaluate two such components of the inflammatory milieu, tumor-associated tissue eosinophilia (TATE) as well as Cyclo-oxygenase-2 (COX-2) gene expression, quantitatively in oral squamous cell carcinoma (OSCC) patients in relation to treatment outcomes and patterns of recurrence.
|
26577687 |
2016 |
Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Subgroup analysis also indicated that Cox-2 expression was significantly correlated with skin cancer with the pathology type of squamous cell carcinoma (OR = 31.95, 95% CI: 15.08-67.72, P < 0.05) and basal cell carcinoma (OR = 14.69, 95% CI: 4.80-44.94, P < 0.05).
|
28230039 |
2016 |
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Factors predicting outcome after salvage treatment for stage IV oral squamous cell carcinoma: Evidence of the potential importance of the cyclooxygenase-2-prostaglandin E2 pathway.
|
24771596 |
2015 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The goal of our study was a comparative evaluation of apoptosis regulators: p53, Bcl-2, Bax, COX-2, and survivin in lung adenocarcinoma (AC) and squamous cell carcinoma (SCC).
|
26022894 |
2015 |
Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The expression of COX-2 in squamous cell carcinoma (73.3 %) was significantly higher than that in keratoacanthoma (12 %) (χ (2) = 20.69, P < 0.05).
|
25575894 |
2015 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In a combination regimen, Sabutoclax and COX-2 inhibitor, Celecoxib, synergistically inhibited the growth of OSCC in vitro and also significantly reduced OSCC tumor growth in vivo.
|
26009874 |
2015 |
Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
There was a strong association between COX-2 overexpression and recurrence of oral squamous cell carcinoma (P < 0.001) and a positive relation between increased MDM2 expression and failure of radiotherapy (P = 0.007).
|
26369479 |
2015 |
Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In contrast, GPR109A activation in keratinocytes induces flushing by activation of Cox-2-dependent inflammatory signaling, and the receptor expression is upregulated in human epidermoid carcinoma.
|
24371223 |
2014 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Moreover, Cox-2(flox/flox);K14Cre(+) papillomas did not progress to squamous cell carcinomas.
|
24469308 |
2014 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
COX-2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors.
|
24345644 |
2014 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cyclooxygenase-2 promotes tumor lymphangiogenesis and lymph node metastasis in oral squamous cell carcinoma.
|
22735610 |
2012 |
Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Special attention has been paid to the expression of cyclooxygenase-2 (COX-2) and its potential role in development of oral squamous cell carcinoma.
|
21923838 |
2012 |
Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
BCC and SCC intra-group analysis showed lower COX-2 activity in C-allele carriers versus non-carriers (p < 0.001 and p < 0.0001, respectively).
|
22159575 |
2012 |
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Results of the present study indicate that these three functional variants in the COX-2 regulatory region may contribute to risk modification of tobacco-related oral squamous cell carcinoma in Asian Indians.
|
20620096 |
2010 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We investigated possible relations between COX-2 and NO with the use of a human epidermoid carcinoma cell line, designated KB, in which overexpression of COX-2 protein was induced by gene transfer.
|
20514441 |
2010 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Multicolor immunohistofluorescence staining confirmed the COX-expression profiles in organotypic 3D cultures and the COX-2 dominance in OSCC tumors.
|
19278989 |
2009 |